Urinary cGMP excretion after hormone replacement therapy in postmenopausal women.
It is well established that estrogens and progestogens are able to influence the vasotonus in postmenopausal women. The present study was undertaken to find out if the NO/cGMP-system is involved in this hormone action. Urinary cGMP excretion which can reflect intracellular cGMP production elicited by NO (EDRF) was investigated in 20 postmenopausal women. In an open cross-over study design norethisterone acetate was administered orally for 8 days, estradiol valerate orally for 9 days and a combination of both substances for 12 days. After all three treatment phases urinary cGMP expressed as percentage of the pretreatment value was increased at a statistically significant level. Due to high individual variations no significant differences could be found among the values after the three treatment phases. It was concluded that the NO/cGMP-system may play a role in maintaining vasotonus in postmenopausal women under hormone replacement therapy.
Mueck
A O
AO
Department of Obstetrics & Gynecology, University of Tübingen, Germany.
Seeger
H
H
Kasspohl-Butz
S
S
Teichmann
A T
AT
Lippert
T H
TH
D000284:Administration, Oral; D018592:Cross-Over Studies; D006152:Cyclic GMP / Q000652:urine*; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D017698:Postmenopause / Q000187:drug effects / Q000652:urine*; D016896:Treatment Outcome
D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D000077563:Norethindrone Acetate; D006152:Cyclic GMP; D009640:Norethindrone